|
Oct 9
|
OptiNose Inc (OPTN) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ...
|
|
Oct 7
|
Optinose Appoints Terry Kohler as Chief Financial Officer
|
|
Jun 27
|
Expanded Access to XHANCE with Addition to National Commercial Formularies
|
|
May 15
|
Q1 2024 OptiNose Inc Earnings Call
|
|
May 15
|
OptiNose Inc (OPTN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...
|
|
May 14
|
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 14
|
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
|
|
May 10
|
OptiNose Inc (OPTN) Announces $55 Million Financing Round Amidst Revenue Projections
|
|
May 10
|
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
|
|
May 9
|
Optinose Announces $55 Million Registered Direct Offering
|
|
May 5
|
Recent uptick might appease OptiNose, Inc. (NASDAQ:OPTN) institutional owners after losing 50% over the past year
|
|
May 3
|
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
|
|
May 2
|
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 25
|
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
|
|
Apr 6
|
OptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years ago
|
|
Apr 4
|
Optinose to Present at the Needham Virtual Healthcare Conference
|
|
Mar 15
|
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
|
|
Mar 10
|
US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results
|
|
Mar 8
|
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript
|
|
Mar 8
|
OptiNose Full Year 2023 Earnings: EPS Beats Expectations
|